A Phase 3, Open-Label Study Of Elranatamab Monotherapy Versus Elotuzumab, Pomalidomide, Dexamethasone (Epd) Or Pomalidomide, Bortezomib, Dexamethasone (Pvd) Or Carfilzomib, Dexamethasone (Kd) In Participants With Relapsed/ Refractory Multiple Myeloma Who Received Prior Anti-Cd38 Directed Therapy (C1071032) (MAGNETISMM-32)

Research summary

This study is a Phase 3, open-label, multi-center, randomized study to evaluate the efficacy and safety of elranatamab monotherapy versus the investigator’s choice of elotuzumab, pomalidomide, dexamethasone (EPd) or pomalidomide, bortezomib, dexamethasone (PVd) or carfilzomib, dexamethasone (Kd) in participants with RRMM who have received at least 1 but no more than 4 prior lines of therapy including an anti-CD38 antibody and lenalidomide. Participants will have RRMM and relapsed or refractory to the last anti-myeloma treatment regimen and will not have received previous treatment with a BCMA-directed therapy. Approximately 492 participants will be enrolled using a 1:1 randomization ratio, stratified by prior lines of therapy (1 vs 2-4) and ISS disease stage (1-2 vs 3). Enrolment of participants who have previously received 4 prior lines of therapy will be restricted to a maximum of 20%.

Principal Investigator

Dr Jaimal Kothari

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1008900